The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

The study, “… A European Medicines Agency (EMA) committee has recommended the approval of Novo Nordisk’s concizumab as a prophylactic, or preventive, treatment for adults and children, ages 12 and ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co. (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks ...

It might seem odd to group Eli Lilly and Novo Nordisk, but these drugmakers have much in common. They've been the leaders in the diabetes drug market for decades, and both are now pioneering the ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...